Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Monoclonal Antibody-Based Therapy Strategies: Providing Options for the Cancer Patient

Author(s): Diane E. Milenic

Volume 8, Issue 19, 2002

Page: [1749 - 1764] Pages: 16

DOI: 10.2174/1381612023393963

Price: $65


Treatment of patients with unconjugated MAb such as rituximab (Rituxan) the anti-CD20 MAb or trastuzumab (Herceptin) the anti-Her2 MAb, have shown efficacy in clinical trials and have gained approval from the Food and Drug Administration (FDA) has a result. Likewise, an anti-CD33 MAb conjugated with the antibiotic calicheamicin (Mylotarg) has proven efficacious in the treatment of patients with acute myeloid leukemia and has also been approved by the FDA. This overview presents some of the monoclonal antibody (MAb)-guided strategies with a focus on some of the experiences reported for MAb evaluated in clinical trials.

Keywords: therapy strategies, rituximab (rituxan), immunology today, potential therapeutic sfficacy, generation of antibodies, anti-idiotype, immunoconjugates, radioiodines and astatine

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy